Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Clinical trial NCT05699655 · RECRUITING

Trial details

NCT number: NCT05699655
Sponsor: Fujian Cancer Hospital
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Immunotherapy Gastrict Cancer

Start date: 2023-05-10
Primary completion: 2025-03-01
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.